Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

por Frost, Charles E., Ly, Van, Garonzik, Samira M.
Publicado 2021

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

por Byon, Wonkyung, Garonzik, Samira, Boyd, Rebecca A., Frost, Charles E.
Publicado 2019

The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study

por Garonzik, Samira, Byon, Wonkyung, Myers, Elsa, Li, Xiodong, Marchisin, David, Murthy, Bindu
Publicado 2019

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach

por Garonzik, Samira M., Lenhard, Justin R., Forrest, Alan, Holden, Patricia N., Bulitta, Jϋrgen B., Tsuji, Brian T.
Publicado 2016

Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition

por Meah, Mohammed N., Raftis, Jennifer, Wilson, Simon J., Perera, Vidya, Garonzik, Samira M., Murthy, Bindu, Everlof, J. Gerry, Aronson, Ronald, Luettgen, Joseph, Newby, David E.
Publicado 2020

PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation

por Wilson, Simon J., Ismat, Fraz A., Wang, Zhaoqing, Cerra, Michael, Narayan, Hafid, Raftis, Jennifer, Gray, Timothy J., Connell, Shea, Garonzik, Samira, Ma, Xuewen, Yang, Jing, Newby, David E.
Publicado 2018